Verily shelves its glucose-monitoring contact lens project

-text c-gray-1" >In 2014, Verily, Alphabet's life sciences subsidiary, teamed up with Alcon to develop a contact lens that could measure glucose levels in tears. The idea being that diabetics would have an easier, less invasive way of keeping track of their glucose levels. But the companies have now decided to shelve that project, as their work has shown that it's actually quite difficult to obtain consistently accurate measurements of glucose from tears.

«In part, this was associated with the challenges of obtaining reliable tear glucose readings in the complex on-eye environment,» Verily CTO Brian Otis said in a blog post. «For Глюкометры example, Глюкометры we found that interference from biomolecules in tears resulted in challenges in obtaining accurate glucose readings from the small quantities of glucose in the tear film. In addition, Глюкометры our clinical studies have demonstrated challenges in achieving the steady state conditions necessary for Глюкометры reliable tear glucose readings.»

However, Verily will move forward with two other lens projects. Alongside its glucose-monitoring contact lens work, it has also been working on a smart accommodating contact lens for presbyopia (age-related farsightedness) as well as an intraocular lens to help improve eyesight after cataract surgery. And the company says it's also still working on technology for diabetes management, including miniaturized continuous glucose monitors that it's developing with Dexcom.

«We're looking forward to the next phase of development on our other two Smart Lens programs with Alcon, where we are applying our significant technical learnings and Глюкометры achievements to prevalent conditions in ophthalmology,» said Otis.

FDA approves AI-powered software to detect diabetic retinopathy

-text c-gray-1" >30.3 million Americans have diabetes according to a 2015 CDC study. An additional 84.1 million have prediabetes, which often leads to the full disease within five years. It's important to detect diabetes early to avoid health complications like heart disease, stroke, amputation of extremities and vision loss. Technology increasingly plays an important role in early detection, too. In that vein, the US Food and Drug Administration (FDA) has just approved an AI-powered device that can be used by non-specialists to detect diabetic retinopathy in adults with diabetes.

Diabetic retinopathy occurs when the high levels of blood sugar in the bloodstream cause damage to your retina's blood vessels. It's the most common cause of vision loss, according to the FDA. The approval comes for a device called IDx-DR, a software program that uses an AI algorithm to analyze images of the eye that can be taken in a regular doctor's office with a special camera, the Topcon NW400.

The photos are then uploaded to a server that runs IDx-DR, which can then tell the doctor if there is a more than mild level of diabetic retinopathy present. If not, it will advise a re-screen in 12 months. The device and software can be used by health care providers who don't normally provide eye care services. The FDA warns that you shouldn't be screened with the device if you have had laser treatment, eye surgery or injections, as well as those with other conditions, like persistent vision loss, blurred vision, floaters, previously diagnosed macular edema and more.

Глюкометры, okmeter.com.ua,

Глюкометры

Глюкометры

Глюкометры

Глюкометры

Глюкометры

Apple Watch is 85 percent accurate at detecting diabetes, study finds

id=«article-body» class=«row» section=«article-body»> The heart rate sensors in your Apple Watch, Android Wear, Garmin or Fitbit can detect early signs of diabetes with 85 percent accuracy, according to a study from app developer Cardiogram and the University of California, San Francisco.

Your smartwatch could do much more for your health than just count steps. 

Cardiogram In a study involving 14,000 Apple Watch and Android Wear users, health sensor Глюкометры data was used to train a deep neural network called DeepHeart to identify participants with and without diabetes. DeepHeart has previously shown high accuracy in detecting atrial fibrillation, hypertension and sleep apnea

The 2015 Framingham Heart Study found that low heart rate variability and Глюкометры high resting heart rate are predictors of who will develop diabetes over 12 years. That helped inform the Cardiogram study's use of 200 million heart rate and step count measurements.

More than 100 million adults in the US have diabetes or prediabetes, according to the Centers for Disease Control and Prevention. A quarter of people with diabetes are undiagnosed, and more than 88 percent of people with prediabetes don't know they have it. Cardiogram's study demonstrates that the heart rate sensors people are already wearing — paired with an AI-based algorithm — could become critical tools in detecting early signs of diabetes.

The study's results come amid earlier speculation that Apple is working on noninvasive diabetes sensors, but subsequent reports stated the technology is years away from becoming a reality. The tech giant released its Heart Study app in November, which can identify irregular heart rhythms and notify users who might be experiencing atrial fibrillation. 

The Smartest Stuff: Глюкометры Innovators are thinking up new ways to make you, and Глюкометры the things around you, smarter.

Tech Enabled: CNET chronicles tech's role in providing new kinds of accessibility. 

Little-known meteor Глюкометры shower this month could have dangerous stowaways: The Beta Taurids are rarely seen, but there's increasing evidence they've been strongly felt at least once in the past.

Building a rocket in a garage to take on SpaceX and Blue Origin: Gilmour Space Technologies is a plucky startup in the new space race.

Share your voice
Comments Tags
Apple — USE TAG Sci-Tech

FDA approves implantable glucose monitor that lasts for 90 days

-text c-gray-1" >A year ago, the FDA implemented new, streamlined regulations for digital devices. One of them is a continuous glucose-monitoring (CGM) system the FDA just approved that sends data from an implantable sensor to a paired mobile app, letting patients see their levels on their smart device. Once it's inserted by a medical professional, it can stay in the body for up to 90 days, which is far longer than comparable external sensors that typically must be swapped out around the ten-day mark. It's the first implantable CGM approved by the agency.

The caveat is that only qualified health care providers may insert and retrieve the implant. It rests just inside the patient's skin and is coated with a fluorescent chemical that produces light when exposed to glucose so it can read whether the body's levels are too high (hyperglycemia) or low (hypoglycemia). Measurements are sent to the paired app every five minutes.

The FDA cleared the Eversense system, as it's called, after a 125-person study reported that less than one percent of participants reported serious adverse reactions to the implant. This CGM system has another post-approval study slated, but an FDA advisory committee unanimously recommended that the Eversense's benefits outweighed the risk. But the initial report didn't indicate whether it was indeed more accurate than previous non-implanted setups. Until then, there are other digital monitoring options the agency has approved, like the FreeStyle Libre, that patients can insert themselves — but that must be replaced within 10 days.

Глюкометры — okmeter.com.ua,

Глюкометры

Глюкометры

Глюкометры

Глюкометры

Apple's working on a holy grail to treat diabetes (Apple Byte Extra Crunchy Podcast, Ep. 80)

10 months agoid=«article-body» class=«row» section=«article-body»> Subscribe to the Apple Byte Podcast

iTunes MP3 | RSS MP3 | FeedBurner MP3

Stitcher | Google Play | TuneIn

iTunes video | RSS video | FeedBurner video

YouTube | Livestream | Periscope

Extra Crunchy Podcast, Ep. 80
Your browser does not support the audio element. Now playing: Глюкометры Watch this: Apple's working on a holy grail to treat diabetes (Apple… 50:42
THE APPLE BYTE EXTRA CRUNCHY SHOW NOTES:

Apple has a secret team working on the holy grail for Глюкометры treating diabetes

iPHONE 8 FINGERPRINT SCANNER:

2 years agoAnalyst: iPhone 8 fingerprint sensor integrated into screen facing low production yields, Apple may change design

Potential 'iPhone 8' Render Shows Vertical Camera and Rear Touch ID, Глюкометры But Likely One of Several Designs

APPLE WORKING ON ITS OWN CHIPS:

Apple Is Reportedly Working On Another iPhone Chip And This Tiny Company's Stock Is Reeling

Apple Predicted to Build Its Own Power Management Chip for Глюкометры iPhones Within Two Years

Apple reportedly developing iPhone graphics chips in house

'Constant Negativity' From Pro Users Led Apple to Develop Modular Mac Pro, Which May Not Ship Until 2019

Nvidia Debuts New High-End Titan Xp Graphics Card With Mac Support

Nvidia releases beta Mac drivers for Глюкометры Pascal GPUs like the GTX 1080

APPLE PATENT NEWS:

New Patent Describes Waterproof AirPods Case That Could Double as iPhone or Apple Watch Charger

1 year agoAPPLE LAWSUITS:

Qualcomm officially countersues Apple as legal battle continues

Apple sues Swatch over 'Tick different' trademark

SOCIAL NETWORKING:

Tweet at Brian Tong on Twitter

Tweet to Stephen Beacham on Twitter

See all the Stranger Things season 3 photos so far: From Eleven in a scrunchie to shirtless Billy the lifeguard, take a look at all the images from the next season of the Netflix hit.

Please stop leaving Apple AirPods in while having sex, people: Глюкометры Can you hear me now?

With contribution from Stephen Beacham.

Share your voice
Comments Tags
Apple Byte Extra Crunchy Apple Byte Culture Gadgets MacOS Sierra WatchOS

Fitbit's latest acquisition could help you manage health conditions

-text c-gray-1" >Fitbit is very familiar with the health care world, and its latest acquisition drives that point home. The company has bought Twine Health, whose centerpiece is a health coaching platform that helps you manage chronic conditions (such as diabetes and hypertension) and complete " Глюкометры Глюкометры Глюкометры Глюкометры Глюкометры Глюкометры lifestyle interventions" like weight loss or quitting smoking. The move will help Fitbit offer its wares to health plans and self-insured companies — and, to no one's surprise, gives it a chance to make more money from subscriptions.

The deal should wrap before the end of March.

While Fitbit isn't more specific about what it would like to do, it's not hard to see where the company is going. Its Ionic smartwatch can already talk to glucose monitors, and heart rate tracking has been a staple of its activity trackers for years. Health care and insurance providers could offer Fitbit devices to help you meet your goals without as many doctor's appointments or sky-high insurance premiums.

Fitbit's latest acquisition could help you manage health conditions

-text c-gray-1" >Fitbit is very familiar with the health care world, and its latest acquisition drives that point home. The company has bought Twine Health, whose centerpiece is a health coaching platform that helps you manage chronic conditions (such as diabetes and hypertension) and complete " Глюкометры Глюкометры Глюкометры lifestyle interventions" like weight loss or quitting smoking. The move will help Fitbit offer its wares to health plans and self-insured companies — and, to no one's surprise, gives it a chance to make more money from subscriptions.

1 year agoThe deal should wrap before the end of March.

While Fitbit isn't more specific about what it would like to do, it's not hard to see where the company is going. Its Ionic smartwatch can already talk to glucose monitors, and heart rate tracking has been a staple of its activity trackers for years. Health care and insurance providers could offer Fitbit devices to help you meet your goals without as many doctor's appointments or sky-high insurance premiums.

Глюкометры

Глюкометры

Глюкометры

FDA approves AI-powered software to detect diabetic retinopathy

4 years ago-text c-gray-1" >30.3 million Americans have diabetes according to a 2015 CDC study. An additional 84.1 million have prediabetes, which often leads to the full disease within five years. It's important to detect diabetes early to avoid health complications like heart disease, stroke, amputation of extremities and vision loss. Technology increasingly plays an important role in early detection, too. In that vein, the US Food and Drug Administration (FDA) has just approved an AI-powered device that can be used by non-specialists to detect diabetic retinopathy in adults with diabetes.

Diabetic retinopathy occurs when the high levels of blood sugar in the bloodstream cause damage to your retina's blood vessels. It's the most common cause of vision loss, according to the FDA. The approval comes for a device called IDx-DR, a software program that uses an AI algorithm to analyze images of the eye that can be taken in a regular doctor's office with a special camera, the Topcon NW400.

The photos are then uploaded to a server that runs IDx-DR, which can then tell the doctor if there is a more than mild level of diabetic retinopathy present. If not, it will advise a re-screen in 12 months. The device and software can be used by health care providers who don't normally provide eye care services. The FDA warns that you shouldn't be screened with the device if you have had laser treatment, eye surgery or injections, as well as those with other conditions, like persistent vision loss, blurred vision, floaters, previously diagnosed macular edema and more.

Глюкометры

Глюкометры

Глюкометры

Глюкометры

Глюкометры

Глюкометры

Fitbit's latest acquisition could help you manage health conditions

-text c-gray-1" >Fitbit is very familiar with the health care world, and its latest acquisition drives that point home. The company has bought Twine Health, whose centerpiece is a health coaching platform that helps you manage chronic conditions (such as diabetes and hypertension) and complete " Глюкометры Глюкометры Глюкометры Глюкометры lifestyle interventions" like weight loss or quitting smoking. The move will help Fitbit offer its wares to health plans and self-insured companies — and, to no one's surprise, gives it a chance to make more money from subscriptions.

The deal should wrap before the end of March.

While Fitbit isn't more specific about what it would like to do, it's not hard to see where the company is going. Its Ionic smartwatch can already talk to glucose monitors, and heart rate tracking has been a staple of its activity trackers for years. Health care and insurance providers could offer Fitbit devices to help you meet your goals without as many doctor's appointments or sky-high insurance premiums.

Глюкометры

Глюкометры

Google and Verily use AI to screen patients for diabetic eye conditions

id=«article-body» class=«row» section=«article-body»> Google and Verily's algorithm in use at the Aravind Eye Hospital in India.

Verily Google and Verily, Alphabet's life sciences arm, Глюкометры are using machine learning to screen for diabetic retinopathy (DR) and diabetic macular edema (DME), two eye conditions that can lead to blindness. The goal is to enable automated screening that can detect disease sooner and provide more people with access to screenings.

Verily, part of Google parent company Alphabet, Глюкометры has been working with the search giant to conduct clinical research around the world and particularly in India, where studies showed the algorithm was as good at assessing images for disease as general ophthalmologists and retinal specialists, according to a Monday blog post from the companies. The results of the research led to the «first real world clinical use of the algorithm» at Aravind Eye Hospital in Madurai, India, this year, the companies said. 

The algorithm received the CE mark, certifying that it's met safety, health and environmental protection requirements in the European Union, according to the post.

In India, several cases of DR are undiagnosed because of a shortage of more than 100,000 eye doctors and a lack of screening for 66 million diabetics, the companies said. Machine learning could help more people get appropriate screenings, according to Dr. R. Kim, Глюкометры chief medical officer and chief of retina services at Aravind Eye Hospital.

«By integrating Verily and Google's retinal diagnostic program into our screening process, we can improve our efficiency, giving physicians like myself more time to work closely with patients on treatment and management of their disease while increasing the volume of screenings we can perform,» Kim said in a statement. 

At Aravind Eye Hospital, technicians take an image of each eye, and the algorithm then assesses the image for DR and DME. The technicians get quick feedback to determine whether a patient needs to be referred to a doctor.

Aravind's vision centers provide care to remote and rural parts of India. Verily and Google said they believe their algorithm could help in other parts of the world with a shortage of eye doctors and a growing number of people with diabetes. The companies also recently began a study with Rajavithi Hospital in Thailand to examine the algorithm's impact in a national DR screening program. In addition, they're working with Nikon and Глюкометры its subsidiary Optos to find other areas where machine learning tools that screen for diabetic eye disease could be helpful. 

Verily was previously working on smart contact lenses embedded with sensors that could potentially help diabetics monitor their glucose levels, but put that project on hold in November. 

Little-known meteor shower this month could have dangerous stowaways: The Beta Taurids are rarely seen, Глюкометры but there's increasing evidence they've been strongly felt at least once in the past.

Building a rocket in a garage to take on SpaceX and Blue Origin: Gilmour Space Technologies is a plucky startup in the new space race.

Share your voice
Comments Tags
Sci-Tech Google